Series B · Medtech & Devices · Rome, Italy · Founded 2015 · 51–100 employees
ADOR Diagnostics is developing the NATlab system, a revolutionary point-of-care molecular diagnostics platform that uses novel isothermal rolling circle amplification (RCA) technology to rapidly diagnose infectious diseases in 30-60 minutes. The company's multiplex syndromic testing approach can analyze up to 100 targets per sample, significantly faster than traditional PCR methods. Founded as a strategic partnership between Italian company Adaltis and Dutch company Gamida, ADOR has raised $7.5 million in October 2023 and has total funding of $41.5 million. The company is conducting preclinical trials and expects the total addressable market for NATlab to grow to $15.8 billion by 2025.
No open roles listed right now.